GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Checkpoint Therapeutics Inc (NAS:CKPT) » Definitions » Earnings per Share (Diluted)

CKPT (Checkpoint Therapeutics) Earnings per Share (Diluted) : $-1.43 (TTM As of Dec. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Checkpoint Therapeutics Earnings per Share (Diluted)?

Checkpoint Therapeutics's Earnings per Share (Diluted) for the three months ended in Dec. 2024 was $-0.69. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was $-1.43.

Checkpoint Therapeutics's EPS (Basic) for the three months ended in Dec. 2024 was $-0.69. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2024 was $-1.43.

Checkpoint Therapeutics's EPS without NRI for the three months ended in Dec. 2024 was $-0.69. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2024 was $-1.43.

During the past 3 years, the average EPS without NRIGrowth Rate was 42.50% per year. During the past 5 years, the average EPS without NRI Growth Rate was 22.40% per year.

During the past 10 years, Checkpoint Therapeutics's highest 3-Year average EPS without NRI Growth Rate was 42.50% per year. The lowest was -32.10% per year. And the median was 12.40% per year.


Checkpoint Therapeutics Earnings per Share (Diluted) Historical Data

The historical data trend for Checkpoint Therapeutics's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Checkpoint Therapeutics Earnings per Share (Diluted) Chart

Checkpoint Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Earnings per Share (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.10 -7.45 -7.09 -3.17 -1.42

Checkpoint Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Earnings per Share (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.10 -0.33 -0.18 -0.23 -0.69

Competitive Comparison of Checkpoint Therapeutics's Earnings per Share (Diluted)

For the Biotechnology subindustry, Checkpoint Therapeutics's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Checkpoint Therapeutics's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Checkpoint Therapeutics's PE Ratio distribution charts can be found below:

* The bar in red indicates where Checkpoint Therapeutics's PE Ratio falls into.


;
;

Checkpoint Therapeutics Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

Checkpoint Therapeutics's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2024 is calculated as

Diluted Earnings Per Share (A: Dec. 2024 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-56.24-0)/39.674
=-1.42

Checkpoint Therapeutics's Earnings Per Share (Diluted) for the quarter that ended in Dec. 2024 is calculated as

Diluted Earnings Per Share (Q: Dec. 2024 )=(Net Income - Preferred Dividends / Shares Outstanding (Diluted Average)
=(-28.9-0)/46.027
=-0.63

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.43

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.


Checkpoint Therapeutics  (NAS:CKPT) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Checkpoint Therapeutics Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of Checkpoint Therapeutics's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Checkpoint Therapeutics Business Description

Traded in Other Exchanges
Address
95 Sawyer Road, Suite 110, Waltham, MA, USA, 02453
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor ("EGFR") inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.
Executives
Oliviero James F Iii director, officer: CEO, President and Director C/O KERYX BIOPHARMACEUTICALS, INC., 750 LEXINGTON AVENUE, NEW YORK NY 10022
William Garrett Gray officer: See Remarks 2 GANSEVOORT STREET,, 9TH FLOOR, NEW YORK NY 10014
Fortress Biotech, Inc. 10 percent owner 1111 KANE CONCOURSE, SUITE 301, BAY HARBOR ISLANDS FL 33154
Michael S Weiss director 750 LEXINGTON AVE, NEW YORK NY 10022
Neil Herskowitz director 2109 BROADWAY, SUITE 206, NEW YORK NY 10023
Christian Bechon director C/O LFB, 3, AVENUE DES TROPIQUES, LES ULIS, COURTABOEUF I0 91940
Barry M Salzman director 464 COMMON STREET, SUITE 301, BELMONT MA 02478
Scott Boilen director 2 SKYLINE DRIVE, HAWTHORNE NY 10532
Rosenwald Lindsay A Md director 375 PARK AVE, NEW YORK NY 10152
David J Horin officer: Interim CFO 1270 AVENUE OF THE AMERICAS, 16TH FLOOR, NEW YORK NY 10020